Breaking News

Tweet TWEET

Navidea Biopharmaceuticals Announces the Presentation of Lymphoseek® Data at Upcoming Scientific Meetings

  Navidea Biopharmaceuticals Announces the Presentation of Lymphoseek® Data at
  Upcoming Scientific Meetings

     – Data from Lymphoseek studies to be presented at the  International
Conference on Innovative Approaches in Head and Neck Oncology,  AACR-SNMMI and
                                    SSO –

Business Wire

DUBLIN, Ohio -- February 7, 2013

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company
focused on precision diagnostic radiopharmaceuticals, today announced that
data from its Lymphoseek^® (technetium Tc 99m tilmanocept) Injection studies
in breast cancer and melanoma or head and neck cancer are being presented at
the following conferences: The 4^th International Conference on Innovative
Approaches In Head And Neck Oncology  in Barcelona, Spain, the joint meeting
of AACR and the Society of Nuclear Medicine and Molecular Imaging in San
Diego, CA and the 66^th Society of Surgical Oncology Cancer Symposium in
Washington, DC. Details of the poster presentations are listed below.

Conference:         4^th International Conference on Innovative
                          Approaches in Head And Neck Oncology (ICHNO)
Date:                     February 7-9, 2013
Location:                 Barcelona, Spain

Poster Title:             Utilization of Tc99m-tilmanocept to assess sentinel
                          lymph node status in HNSCC patients

Author:                   Stephen Y. Lai, MD, PhD, FACS, The University of
                          Texas MD Anderson Cancer Center, Houston, TX


                          American Association for Cancer Research (AACR) and
Conference:               the Society of Nuclear Medicine and Molecular
                          Imaging (SNMMI)
Date:                     February 27 – March 2, 2013
Location:                 San Diego, CA

                          Evaluation of human mannose receptor (CD206) binding
Poster Title:             of Tc 99m tilmanocept: A novel bio-targeted sentinel
                          node mapping agent for solid tumors

Author:                   Michael Blue, MD, Senior Medical Director, Navidea
                          Biopharmaceuticals


Conference:               66^th Society of Surgical Oncology Cancer Symposium
Date:                     March 6-9, 2013
Location:                 Washington, DC
                          
                          Utilization of Tc 99m tilmanocept to evaluate the
                          pathology status of sentinel lymph nodes vs.
Poster Title:             elective neck dissection in patients with intraoral
                          HNSCC: A preliminary evaluation against technetium
                          Tc 99m sulfur colloid in the ACOSOG-Z0360

Author:                   Stephen Y. Lai, MD, PhD, FACS, The University of
                          Texas MD Anderson Cancer Center, Houston, TX
                          

About Lymphoseek^®

Lymphoseek^® (technetium Tc 99m tilmanocept) Injection is a novel,
receptor-targeted, small-molecule, investigational radiopharmaceutical used in
lymphatic mapping procedures that are performed to help stage cancers such as
breast cancer and melanoma. Lymphoseek is designed to identify the lymph nodes
that drain from a primary tumor, which have the highest probability of
harboring cancer.

Lymphatic mapping is a procedure in which lymph nodes that may contain tumor
metastases are identified and biopsied to determine if cancer has spread
beyond the primary tumor. Accurate staging of cancer is critical, as it guides
therapy decisions and determines patient prognosis and risk of recurrence.
According to the American Cancer Society, approximately 229,000 new cases of
breast cancer, 76,000 new cases of melanoma and 67,000 new cases of head and
neck cancers are expected to be diagnosed in the United States in 2012.

About Navidea Biopharmaceuticals, Inc.

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical
company focused on the development and commercialization of precision
diagnostics and radiopharmaceutical agents. Navidea is actively developing
four radiopharmaceutical agent platforms – Lymphoseek^®, NAV4694, NAV5001 and
RIGScan^TM – to help identify the sites and pathways of undetected disease and
enable better diagnostic accuracy, clinical decision-making and, ultimately,
patient care. Navidea’s strategy is to deliver superior growth and shareholder
return by bringing to market novel radiopharmaceutical agents and advancing
the Company’s pipeline through selective acquisitions, global partnering and
commercialization efforts. For more information, please visit www.navidea.com.

Contact:

Navidea Biopharmaceuticals, Inc.
Brent Larson, Sr. VP & CFO – (614) 822-2330
 
Press spacebar to pause and continue. Press esc to stop.